Tista' taqra bil- Malti.
A medical expert has certified that the anti-Covid drug produced by Moderna had high levels of efficacy. “mRNA-1273 produced high levels of binding and neutralizing antibodies that declined slightly over time, as expected, but they remained elevated in all participants three months after the booster vaccination”, said Dr Alicia T. Widge M.D. of Vaccine Research Center. She was referring to Phase 1 study of the Moderna Covid-19 vaccine.
The letter to the editor was published in the authoritative New England Journal of Medicine and reported that participants in the Phase 1 study of Moderna’s COVID-19 vaccine, retained high levels of neutralizing antibodies through 119 days following first vaccination (90 days following second vaccination). The study was led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in the United States.
The latest announcement follows other declarations made on November 30 that the data analysis indicates a vaccine efficacy of 94.1%.
“These interim Phase 1 data suggests that mRNA-1273, our COVID-19 vaccine, can generate durable neutralizing antibodies across all age groups including in older and elderly adults,” said expert Dr Tal Zaks, Chief Medical Officer of Moderna. “These data give us further optimism to expect that the high level of efficacy recently demonstrated by mRNA-1273 to prevent COVID-19 disease will be durable.”
Britain to start vaccination next week
Earlier this week Britain announced that vaccinations will come next week. The UK became the first country in the world to approve the Pfizer-BioNTech vaccine for use and said that it will be rolled out from next week.
Malta government said that it will be relying on the advice and assessment being carried out by the European Medicines Agency. Results are expected in the coming weeks.